U.S. markets open in 2 hours 39 minutes

Reata Pharmaceuticals, Inc. (RETA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
117.15+3.78 (+3.33%)
At close: 4:00PM EST

Reata Pharmaceuticals, Inc.

5320 Legacy Drive
Plano, TX 75024
United States
972 865 2219
http://www.reatapharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees220

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Warren HuffChairman, CEO & Pres1.2MN/A1954
Mr. Manmeet Singh SoniCOO, CFO & Exec. VP1.01MN/A1978
Mr. Michael D. WortleyExec. VP & Chief Legal Officer724.2k2.4M1948
Dr. Colin J. MeyerExec. VP and Chief R&D Officer835.07k41.18k1979
Ms. Dawn Carter BirExec. VP & Chief Commercial Officer666.15kN/A1971
Ms. Elaine CastellanosVP & Chief Accounting OfficerN/AN/AN/A
Mr. Kevin A. JohnstonVP & Chief Technical OfficerN/AN/AN/A
Dr. W. Christian WigleySr. VP, Chief Scientific Officer & Founding ScientistN/AN/AN/A
Mr. Dakota GallivanVP & Chief Healthcare Compliance OfficerN/AN/AN/A
Ms. Claudia BujoldVP of MarketingN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.

Corporate Governance

Reata Pharmaceuticals, Inc.’s ISS Governance QualityScore as of January 22, 2021 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.